Controlled pulmonary drug and gene delivery using polymeric nano-carriers

被引:171
作者
Beck-Broichsitter, Moritz [1 ]
Merkel, Olivia M. [1 ]
Kissel, Thomas [1 ]
机构
[1] Univ Marburg, Dept Pharmaceut & Biopharm, D-35037 Marburg, Germany
关键词
Pulmonary drug delivery; Gene therapy; Inhalation; Nanoparticles; Isolated lung model; MODIFIED POLY(VINYL ALCOHOL); LOW-MOLECULAR-WEIGHT; CELL-CULTURE MODELS; ACETATE-CO-VINYL; IN-VIVO; BRANCHED POLYESTERS; BIODEGRADABLE NANOPARTICLES; PLGA NANOPARTICLES; RESPIRATORY-TRACT; TARGETED DELIVERY;
D O I
10.1016/j.jconrel.2011.12.004
中图分类号
O6 [化学];
学科分类号
070301 [无机化学];
摘要
Pulmonary drug and gene delivery to the lung represents a non-invasive avenue for local and systemic therapies. However, the respiratory tract provides substantial barriers that need to be overcome for successful pulmonary application. In this regard, micro- and nano-sized particles offer novel concepts for the development of optimized therapeutic tools in pulmonary research. Polymeric nano-carriers are generally preferred as controlled pulmonary delivery systems due to prolonged retention in the lung. Specific manipulation of nano-carrier characteristics enables the design of "intelligent" carriers specific for modulation of the duration and intensity of pharmacological effects. New formulations should be tested for pulmonary absorption and distribution using more advanced ex vivo and in vivo models. The delivery of nano-carriers to the air-space enables a detailed characterization of the interaction between the carrier vehicle and the natural pulmonary environment. In summary, polymeric nanoparticles seem to be especially promising as controlled delivery systems and represent a solid basis for future advancement for pulmonary delivery applications. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:214 / 224
页数:11
相关论文
共 142 条
[1]
In vitro and in vivo testing methods for respiratory drug delivery [J].
Agu, Remigius U. ;
Ugwoke, Michael I. .
EXPERT OPINION ON DRUG DELIVERY, 2011, 8 (01) :57-69
[2]
Biodegradation and biocompatibility of PLA and PLGA microspheres [J].
Anderson, JM ;
Shive, MS .
ADVANCED DRUG DELIVERY REVIEWS, 1997, 28 (01) :5-24
[3]
Targeted gene delivery to the lung [J].
Aneja, Manish K. ;
Geiger, Johannes-Peter ;
Himmel, Anne ;
Rudolph, Carsten .
EXPERT OPINION ON DRUG DELIVERY, 2009, 6 (06) :567-583
[4]
Synthesis and characterization of PLGA nanoparticles [J].
Astete, Carlos E. ;
Sabliov, Cristina M. .
JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION, 2006, 17 (03) :247-289
[5]
Targeted delivery of nanoparticles for the treatment of lung diseases [J].
Azarmi, Shirzad ;
Roa, Wilson H. ;
Loebenberg, Raimar .
ADVANCED DRUG DELIVERY REVIEWS, 2008, 60 (08) :863-875
[6]
PLGA nanoparticles in drug delivery: The state of the art [J].
Bala, I ;
Hariharan, S ;
Kumar, MNVR .
CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 2004, 21 (05) :387-422
[7]
Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method [J].
Barichello, JM ;
Morishita, M ;
Takayama, K ;
Nagai, T .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1999, 25 (04) :471-476
[8]
Beck-Broichsitter M., 2011, J CONTROL RELEASE, DOI [10.1016/j.jconrel.2011.1010.1030, DOI 10.1016/J.JCONREL.2011.1010.1030]
[9]
Beck-Broichsitter M., 2011, J CONTROL RELEASE, DOI [10.1016/j.jconrel.2011.1009.1058, DOI 10.1016/J.JCONREL.2011.1009.1058]
[10]
Biophysical investigation of pulmonary surfactant surface properties upon contact with polymeric nanoparticles in vitro [J].
Beck-Broichsitter, Moritz ;
Ruppert, Clemens ;
Schmehl, Thomas ;
Guenther, Andreas ;
Betz, Thomas ;
Bakowsky, Udo ;
Seeger, Werner ;
Kissel, Thomas ;
Gessler, Tobias .
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2011, 7 (03) :341-350